Search for tag: "cardiomyopathy"

VALOR- HCM Shows Promise for Patients with Symptomatic Hypertrophic Cardiomyopathy

Presented at ACC as a Late-Breaking Clinical Trial, VALOR-HCM explores Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive…

From  HVTI MEDED 0 likes 9 plays

Alcohol Septal Ablation

Alcohol septal ablation has been performed at Cleveland Clinic since the late 1980’s. Dr. Samir Kapadia describes optimal patients to undergo this procedure and outcomes of septal ablation vs.…

From  HVTI MEDED 0 likes 9 plays

Extended Septal Myectomy

Dr. Nicholas Smedira, Surgical Director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic demonstrates the extended septal myectomy in a patient with hypertrophic cardiomyopathy.

From  batchUser 0 likes 230 plays

Advanced Pacing: Leadless, His Bundle and More

Cleveland Clinic Global EP Summit Innovations in cardiac pacing, including new strategies and emerging data, presented within the context of an interesting case presentation. Topics covered include…

From  ConsultQD Live Admin 0 likes 17 plays

Cardiomyopathy: Update in Genetics and Medical Care

Dr. Steven Nissen, Chief Academic Officer, Chief Academic Officer, Sydell and Arnold Miller Family Heart & Vascular Institute talks about cardiomyopathy with Wilson Tang, MD, Director of…

From  ConsultQD Live Admin2 0 likes 30 plays

Hypertrophic Cardiomyopathy for healthcare providers

Steven Nissen, MD, Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic discusses hypertrophic cardiomyopathy (HCM) with experts: cardiologist Milind…

From  decaens@ccf.org 0 likes 65 plays

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Dr. Mazen Hanna describes the findings of ATTR-ACT, a study aimed at the treatment of transthyretin (TTR) amyloid cardiomyopathy with the medication tafamadis. Those who were treated with the…

From  ConsultQD Live Admin 0 likes 247 plays

Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria

Dr. Desai describes the findings of over 1800 patients obstructive HCM in which they reviewed the 5-year primary event rate across the 3 ESC SCD risk categories. The results of this paper shows that…

From  ConsultQD Live Admin 0 likes 150 plays